Status:
NOT_YET_RECRUITING
Effect of Ginkgo Biloba Extract on Cognitive Function in Acute Ischemic Stroke
Lead Sponsor:
Yi Yang
Conditions:
Acute Ischemic Stroke
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine the effect of ginkgo biloba extract on cognitive function in acute ischemic stroke.
Detailed Description
Vascular brain injury is a common post-stroke complication that can reduce cognitive function and lead to vascular cognitive impairment, placing a significant burden on families and society. The purpo...
Eligibility Criteria
Inclusion
- Patients with a definitive clinical diagnosis of acute ischemic stroke;
- Age≥18 years, regardless of sex；
- Primary education level or higher; baseline MoCA score of 10-25 points;
- Able to complete cognitive scale scoring;
- Informed consent is signed and ginkgo biloba extract therapy is initiated within 14 days of onset.
Exclusion
- Transient ischemic attack；
- Patients who received emergency reperfusion therapy (including intravenous thrombolysis and endovascular thrombectomy) at onset;
- Combined with other neurological diseases, such as neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Lewy body dementia, and frontotemporal dementia), optic neuritis, epilepsy, central nervous system infections (e.g., AIDS and syphilis), traumatic brain injury dementia, etc；
- Currently using psychoactive medications (e.g., antidepressants) or anti-epileptic drugs, or if the time since their last use of these medications was less than 5 half-lives (per the pharmacokinetics of each specific medication; for drugs with unknown half-lives, a 1 month washout period was required)；
- Had a pre-existing diagnosis of a cognitive disorder；
- Currently taking medications intended to improve cognitive function or prevent dementia (e.g., cholinesterase inhibitors, memantine, nootropics), or if the washout period since their last use of these medications was less than 5 half-lives as specified in each drug's pharmacokinetics. For drugs with unknown half-lives, a minimum 1 month washout period was required；
- Severe liver and kidney dysfunction;
- Active ulcer or bleeding diathesis；
- Allergy to preparations containing ginkgo biloba extract；
- Pregnant or lactating women, patients with a life expectancy less than 6 months, and those unable to complete the study for other reason；
- Unwillingness to be followed up or poor treatment compliance;
- Those who are participating in other clinical investigators, or who have participated in other clinical studies within 3 months prior to enrollment;
- Other conditions that the investigators deemed unsuitable for enrollment.
Key Trial Info
Start Date :
March 15 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2027
Estimated Enrollment :
356 Patients enrolled
Trial Details
Trial ID
NCT06140888
Start Date
March 15 2024
End Date
April 1 2027
Last Update
February 28 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.